OCGN – ocugen, inc. (US:NASDAQ)
Stock Stats
News
1/16
12:56 pm
ocgn
Low
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
1/15
07:02 pm
ocgn
Medium
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
1/15
08:15 am
ocgn
High
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
1/13
12:41 pm
ocgn
Medium
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]
1/13
07:00 am
ocgn
Medium
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
8/1/2025
08:25 am
OCGN
-4.5%
IN-LINE
5/9/2025
08:01 am
OCGN
-5.6%
BEAT
3/5/2025
07:02 am
OCGN
-4.4%
IN-LINE
3/5/2025
07:02 am
OCGN
-4.4%
IN-LINE
1/15
08:31 am
ocgn
High
Form 8-K Ocugen, Inc. For: Jan 15
1/6
05:21 pm
ocgn
Low
Form 4 Ocugen, Inc. For: Jan 02 Filed by: Musunuri Shankar
1/6
05:20 pm
ocgn
Low
Form 4 Ocugen, Inc. For: Jan 02 Filed by: Ramachandran Ramesh
12/18
05:17 pm
ocgn
Medium
Form 8-K Ocugen, Inc. For: Dec 12
12/8
11:46 am
ocgn
Low
Form SCHEDULE 13G Ocugen, Inc. Filed by: JANUS HENDERSON GROUP PLC
Show more
Top News Gainers
10/9 Ocugen Announces Share Repurchase Program 32.3%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
Top News Decliners
9/30 Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics -59.3%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3